TE1 Stock Overview
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Bio-Techne Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$64.00 |
52 Week High | US$80.50 |
52 Week Low | US$49.40 |
Beta | 1.22 |
1 Month Change | -5.19% |
3 Month Change | -9.22% |
1 Year Change | -3.03% |
3 Year Change | -22.42% |
5 Year Change | 45.30% |
Change since IPO | 459.20% |
Recent News & Updates
Recent updates
Shareholder Returns
TE1 | DE Life Sciences | DE Market | |
---|---|---|---|
7D | -3.8% | 0.5% | 1.8% |
1Y | -3.0% | -5.1% | 5.7% |
Return vs Industry: TE1 exceeded the German Life Sciences industry which returned -4.6% over the past year.
Return vs Market: TE1 underperformed the German Market which returned 7% over the past year.
Price Volatility
TE1 volatility | |
---|---|
TE1 Average Weekly Movement | 4.3% |
Life Sciences Industry Average Movement | 6.3% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 9.9% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: TE1 has not had significant price volatility in the past 3 months.
Volatility Over Time: TE1's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1976 | 3,050 | Kim Kelderman | https://www.bio-techne.com |
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.
Bio-Techne Corporation Fundamentals Summary
TE1 fundamental statistics | |
---|---|
Market cap | €10.12b |
Earnings (TTM) | €207.75m |
Revenue (TTM) | €1.06b |
49.4x
P/E Ratio9.7x
P/S RatioIs TE1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TE1 income statement (TTM) | |
---|---|
Revenue | US$1.14b |
Cost of Revenue | US$374.82m |
Gross Profit | US$770.18m |
Other Expenses | US$546.06m |
Earnings | US$224.11m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 1.43 |
Gross Margin | 67.26% |
Net Profit Margin | 19.57% |
Debt/Equity Ratio | 22.8% |
How did TE1 perform over the long term?
See historical performance and comparison